Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial

M. Früh; H. B. Ris; A. Xyrafas; S. Peters; R. O. Mirimanoff; O. Gautschi; M. Pless; R. Stupp

doi:10.1093/annonc/mdw251

Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial

M. Früh^*, H. B. Ris, A. Xyrafas, S. Peters, R. O. Mirimanoff, O. Gautschi, M. Pless, R. Stupp

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	1971-1972
Number of pages	2
Journal	Annals of Oncology
Volume	27
Issue number	10
DOIs	https://doi.org/10.1093/annonc/mdw251
State	Published - Oct 2016

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdw251

Cite this

@article{9fcec448c5574ee9b4cee4696ce957bd,

title = "Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial",

author = "M. Fr{\"u}h and Ris, {H. B.} and A. Xyrafas and S. Peters and Mirimanoff, {R. O.} and O. Gautschi and M. Pless and R. Stupp",

note = "Funding Information: The trial was supported by the Swiss Government through the State Secretariat for Education, Research and Innovation, SERI. Sanofi (Switzerland) provided financial contribution and docetaxel free of charge. No funding for this Letter. MP Advisory for Sanofi, SP Honoraria from and Advisory role for: Amgen, Lilly, Pfizer, Roche, Astra Zeneca, Boehringer Ingelheim, MSD, Merk Serono, Celgene, Debiopharm, Novartis and BMS. Other authors: no conflicts. Funding Information: The trial was supported by the Swiss Government through the State Secretariat for Education, Research and Innovation, SERI. Sanofi (Switzerland) provided financial contribution and docetaxel free of charge. ",

year = "2016",

month = oct,

doi = "10.1093/annonc/mdw251",

language = "English (US)",

volume = "27",

pages = "1971--1972",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer

T2 - 10-year follow-up of the SAKK 16/01 trial

AU - Früh, M.

AU - Ris, H. B.

AU - Xyrafas, A.

AU - Peters, S.

AU - Mirimanoff, R. O.

AU - Gautschi, O.

AU - Pless, M.

AU - Stupp, R.

N1 - Funding Information: The trial was supported by the Swiss Government through the State Secretariat for Education, Research and Innovation, SERI. Sanofi (Switzerland) provided financial contribution and docetaxel free of charge. No funding for this Letter. MP Advisory for Sanofi, SP Honoraria from and Advisory role for: Amgen, Lilly, Pfizer, Roche, Astra Zeneca, Boehringer Ingelheim, MSD, Merk Serono, Celgene, Debiopharm, Novartis and BMS. Other authors: no conflicts. Funding Information: The trial was supported by the Swiss Government through the State Secretariat for Education, Research and Innovation, SERI. Sanofi (Switzerland) provided financial contribution and docetaxel free of charge.

PY - 2016/10

Y1 - 2016/10

UR - http://www.scopus.com/inward/record.url?scp=85013310965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013310965&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw251

DO - 10.1093/annonc/mdw251

M3 - Letter

C2 - 27358380

AN - SCOPUS:85013310965

SN - 0923-7534

VL - 27

SP - 1971

EP - 1972

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -

Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this